TS-1905 |
TS-1905; LY-01019; BA-1201 |
Phase 1 Clinical |
Shandong Boan Biotechnology Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung |
Details
|
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) |
Z-CTLs |
Phase 1 Clinical |
Hunan Zhaotai Yongren Biotech Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
FH-2001 |
FH-2001 |
Phase 1 Clinical |
|
Solid tumours |
Details
|
HLX-301 |
HLX-301 |
Phase 2 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours; Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
18F-BMS-986229 |
18F-BMS-986229; [18F]BMS-986229 |
Phase 2 Clinical |
Bristol-Myers Squibb International Corp |
Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
TT-00420/Atezolizumab |
|
Phase 1 Clinical |
TransThera Sciences (Nanjing) Inc |
Gastrointestinal Neoplasms |
Details
|
BS-006 |
BS-006 |
Phase 1 Clinical |
|
Solid tumours; Melanoma; Uterine Cervical Neoplasms |
Details
|
PD-L1 t-haNK cell therapy/Inbakicept/Aldoxorubicin Hydrochloride(Immunitybio) |
|
Phase 2 Clinical |
Immunitybio Inc |
Pancreatic Neoplasms |
Details
|
RG-6084 |
RG-6084; RO-7191863 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Hepatitis B |
Details
|
Gallium [68Ga] Natan recombinant PD-L1 single domain antibody |
SNA-002 |
Phase 1 Clinical |
Smartnuclide Biopharma |
Solid tumours; Neoplasms; Contrast agents |
Details
|
sirpiglenastat |
DRP-104 |
Phase 2 Clinical |
Dracen Pharmaceuticals Inc |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
89Zr-S095012 |
89Zr-S-095012 |
Phase 1 Clinical |
Institut De Recherches Internationales Servier |
Solid tumours |
Details
|
SG12473 |
SG12473; SG-12473 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Hematologic Neoplasms; Solid tumours; Neoplasms |
Details
|
BMS-936559 |
MDX-1105; BMS-936559 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Leukemia, Myelogenous, Chronic; Shock, Septic; HIV Infections; Sepsis; Hodgkin Disease; Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma |
Details
|
FS 118 |
FS-118 |
Phase 2 Clinical |
Merck Serono, F-Star |
Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neoplasm Metastasis |
Details
|
IMM-2510 |
IMM-2510 |
Phase 1 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours |
Details
|
Durvalumab/Gefitinib |
|
Phase 2 Clinical |
Medimmune |
Carcinoma, Non-Small-Cell Lung |
Details
|
QL-301 |
QL-301 |
Phase 1 Clinical |
Qlsf Biotherapeutics Inc |
Neoplasms |
Details
|
QL-415 |
QL-415 |
Phase 1 Clinical |
Qlsf Biotherapeutics Inc |
Neoplasms |
Details
|
EMB-09 |
EMB-09 |
Phase 1 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Solid tumours; Neoplasms |
Details
|
99mTc-NM-01 |
99mTc-NM-01 |
Phase 2 Clinical |
Nanomab Technology Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Dimethylaminomicheliolide Fumarate |
ACT-001 |
Phase 2 Clinical |
Tianjin Accendatech Technology Co Ltd |
Ganglioglioma; Glioblastoma; Optic Neuritis; Central Nervous System Neoplasms; Neuromyelitis Optica; Breast Neoplasms; Glioma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
PM-1022 |
PM-1022 |
Phase 1 Clinical |
Biotheus Inc |
Neoplasms |
Details
|
INCB-099280 |
INCB-099280; INCB-99280 |
Phase 1 Clinical |
Incyte Corp Ltd |
Solid tumours; Carcinoma, Merkel Cell; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Mesothelioma; Microsatellite instability-high cancer; Nasopharyngeal Carcinoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular |
Details
|
CCX-559 |
CCX-559 |
Phase 1 Clinical |
Chemocentryx Inc |
Solid tumours; Neoplasms |
Details
|
Ori-Bs-001 |
Ori-Bs-001 |
Phase 1 Clinical |
OriCell Therapeutics Co Ltd |
Solid tumours |
Details
|
SHS-009 |
SHS-009; SH009; SH-009 |
Phase 1 Clinical |
Nanjing Sanhome Pharmaceutical Co Ltd |
Neoplasms |
Details
|
ABL-501 |
ABL-501 |
Phase 1 Clinical |
Abl Bio Inc |
Solid tumours |
Details
|
Garivulimab |
BGB-A333 |
Phase 1 Clinical |
Beigene Ltd |
Solid tumours; Neoplasms |
Details
|
INCB-086550 |
INCB-086550; INCB-86550 |
Phase 2 Clinical |
Incyte Corp |
Solid tumours; Carcinoma, Renal Cell; Carcinoma; Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular |
Details
|
Emdifen |
|
Phase 1 Clinical |
Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences |
Solid tumours |
Details
|
SL-279252 |
TAK-252; SL-279252 |
Phase 1 Clinical |
Takeda Pharmaceutical Co Ltd, Shattuck Labs Inc |
Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma |
Details
|
KN-052 |
KN-052 |
Phase 1 Clinical |
Suzhou Alphamab Co Ltd |
Solid tumours |
Details
|
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) |
LP-002 |
Phase 2 Clinical |
Taizhou Houde Aoke Technology Co Ltd |
Lymphoma, B-Cell; Solid tumours; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma |
Details
|
INBRX-105 |
ES101; INBRX-105 |
Phase 1 Clinical |
Inhibrx |
Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Esophageal adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) |
|
Phase 1 Clinical |
Tianjin Mycure Medical Technology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
ABSK-043 |
ABSK043 |
Phase 1 Clinical |
ABbisko Therapeutics Co Ltd |
Solid tumours; Neoplasms |
Details
|
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) |
|
Phase 2 Clinical |
Changhai Hospital Of Shanghai |
Pancreatic Neoplasms |
Details
|
HL-301 |
HL-301 |
Phase 2 Clinical |
Hanlim Pharm Co Ltd |
Radiation Pneumonitis; Lung Neoplasms |
Details
|
SHS-006(Nanjing Sanhome Pharmaceutical) |
SHS-006; SH-006; SH006 |
Phase 1 Clinical |
Nanjing Sanhome Pharmaceutical Co Ltd |
Solid tumours |
Details
|
Simridarlimab |
IBI-322; IBI322 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Bone Marrow Neoplasms; Hematologic Neoplasms; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma |
Details
|
LP-008 |
LP-008 |
Phase 1 Clinical |
Lepu Biotech Co Ltd |
Solid tumours |
Details
|
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) |
|
Phase 1 Clinical |
Jiangsu Huaiyu Pharmaceutical Co Ltd |
Solid tumours |
Details
|
FAZ-053 |
FAZ-053; LAE-005; LAE005 |
Phase 2 Clinical |
Novartis Pharma Ag |
Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part |
Details
|
MAX-10181 |
MAX-10181; MAX-1 |
Phase 1 Clinical |
|
Solid tumours; Neoplasms |
Details
|
GNC-035 quadr-specific antibody(baili) |
GNC-035 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
SKB-337 |
SKB337; A-337; SKB-337 |
Phase 1 Clinical |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
RC-98 |
RC-98; RC98 |
Phase 2 Clinical |
RemeGen Co Ltd |
Solid tumours; Stomach Neoplasms |
Details
|
BPI-371153 |
BPI-371153 |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Liver Neoplasms; Solid tumours; Lymphoma; Carcinoma, Non-Small-Cell Lung |
Details
|
TQB-2858 |
TQB-2858 |
Phase 2 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Pancreatic Neoplasms; Neoplasms; Nasopharyngeal Neoplasms; Sarcoma; Endometrial Neoplasms; Uterine Cervical Neoplasms |
Details
|
Durvalumab/Selumetinib sulfate |
|
Phase 1 Clinical |
Astrazeneca Plc |
Neoplasms |
Details
|
Pd-1-pik |
Pd-1-pik |
Phase 1 Clinical |
Huashan Hospital Affiliated To Fudan University |
Glioblastoma |
Details
|
PRS-344 |
PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 |
Phase 2 Clinical |
Pieris Pharmaceuticals Inc, Laboratoires Servier |
Solid tumours |
Details
|
GNC-039 |
GNC-039 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
BJ-005 |
BJ-005 |
Phase 1 Clinical |
Boji Biomedical Technology (Hangzhou) Co Ltd |
Solid tumours; Lymphoma |
Details
|
JS-003 |
JS-003 |
Phase 1 Clinical |
|
Solid tumours |
Details
|
TQB-2868 |
TQB-2868 |
Phase 1 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Neoplasms |
Details
|
ASC-61 |
ASC-61 |
Phase 1 Clinical |
Ascletis Pharma Inc |
Solid tumours; Neoplasms |
Details
|
Betifisolimab |
MSB-2311 |
Phase 1 Clinical |
Mabspace Biomedicine (Suzhou) Co Ltd |
Solid tumours |
Details
|
PF-07257876 |
|
Phase 1 Clinical |
Pfizer Inc |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung |
Details
|
FPT-155 |
CD80-Fc; FPT-155 |
Phase 1 Clinical |
Five Prime Therapeutics Inc |
Solid tumours; Neoplasms |
Details
|
CN-202 |
CN-202 |
Phase 2 Clinical |
Tongrun Biomedicine (Shanghai) Co Ltd |
Solid tumours; Hematologic Neoplasms; Neoplasm Metastasis |
Details
|
Davoceticept |
ALPN-202 |
Phase 1 Clinical |
Alpine Immune Sciences Inc |
Solid tumours; Lymphoma |
Details
|
Sudubrilimab |
HS-636 |
Phase 2 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd |
Triple Negative Breast Neoplasms; Neoplasms; Primary mediastinal B cell lymphoma |
Details
|
Opucolimab |
HLX-20 |
Phase 1 Clinical |
Shanghai Henlius Biotech Inc |
Solid tumours; Neoplasms |
Details
|
BR-102 |
BR102 |
Phase 1 Clinical |
BioRay Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
IBC-Ab002 |
IBC-Ab002 |
Phase 1 Clinical |
ImmunoBrain Checkpoint Inc |
Alzheimer Disease |
Details
|
89Zr-KN035(Wuxi No. 4 People's Hospital) |
|
Clinical |
Wuxi No. 4 People |
Solid tumours |
Details
|
QLF31907 |
QLF31907; QLF-31907 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Neoplasms |
Details
|
Carrizumab |
|
Phase 2 Clinical |
|
Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma |
Details
|
KD-033 |
KD-033 |
Phase 1 Clinical |
Takeda Pharma |
Solid tumours |
Details
|
AN-4005 |
AN-4005 |
Phase 1 Clinical |
Hangzhou Adlai Nortye Biomedical Technology Co Ltd |
Solid tumours; Neoplasms; Lymphoma |
Details
|
RAD-203 |
RAD-203 |
Phase 1 Clinical |
Radiopharm Theranostics Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
IBC-0966 |
IBC-0966 |
Phase 2 Clinical |
Shenghe (China) Biopharmaceutical Co Ltd |
Neoplasms |
Details
|
CAR-T cell therapy (Timmune Biotech) |
|
Phase 1 Clinical |
Tianjin Timmune Biotech Inc |
Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Lesabelimab |
BC-003 |
Phase 2 Clinical |
Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd |
Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Penile Neoplasms |
Details
|
LOR-S03 |
CDX-527 |
Phase 1 Clinical |
Celldex Therapeutics |
Solid tumours; Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
SG-1408 |
SG-1408; SG1408 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Solid tumours |
Details
|
TJ-L14B |
ABL-503; TJ-L14B/ABL503; ABL503 |
Phase 1 Clinical |
I-Mab Biopharma Co Ltd |
Solid tumours |
Details
|
Pacmilimab |
CX-072 |
Phase 2 Clinical |
Cytomx Therapeutics Inc |
Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Lymphoma; Melanoma |
Details
|
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Peritoneal Neoplasms; Pleural Effusion, Malignant |
Details
|
MT-6402 |
MT-6402; MT-64-6402 |
Phase 1 Clinical |
Molecular Templates Inc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung |
Details
|
PD-L1 t-haNK cell therapy |
|
Phase 2 Clinical |
Nantkwest Inc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Neoplasm Metastasis |
Details
|
PM-1003 |
PM1003 |
Phase 2 Clinical |
Biotheus Inc |
Solid tumours |
Details
|
LBL-024 |
LBL024; LBL-024 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Solid tumours; Neoplasms |
Details
|
BAT-7104 |
BAT-7104 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours; Neoplasms |
Details
|
HB-0036 |
HB-0036 |
Phase 2 Clinical |
Huabo Biopharm Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
6MW-3511 |
6MW-3511 |
Phase 2 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Solid tumours; Neoplasms |
Details
|
INCB-099318 |
INCB-099318; INCB-99318 |
Phase 1 Clinical |
Incyte Corp |
Neoplasms; Uterine Cervical Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Microsatellite instability-high cancer; Mesothelioma; Ovarian Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Anus Neoplasms; Solid tumours |
Details
|
IBI-323(Innovent Biologics) |
IBI-323 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
MCLA-145 |
MCLA-145 |
Phase 1 Clinical |
Incyte Corp, Merus Nv |
Solid tumours; Neoplasms |
Details
|
FS-222 |
FS-222 |
Phase 1 Clinical |
F-star Beta Ltd |
Neoplasms; Neoplasm Metastasis |
Details
|
18F-BMS-986192 |
BMS-986192-[18F] |
Clinical |
Bristol-Myers Squibb Company |
Neoplasms |
Details
|
89Zr-durvalumab |
|
Phase 2 Clinical |
Radboud University Nijmegen |
Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
ADG-104 |
ADG-104; ADG104 |
Phase 2 Clinical |
Guilin Sanjin Pharmaceutical Co Ltd, Adagene Inc |
Neoplasms |
Details
|
QLS31901 |
QLS-31901; QLS31901 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Neoplasms |
Details
|
TST-005 |
TST-005; TST005 |
Phase 1 Clinical |
Mabspace Biomedicine (Suzhou) Co Ltd |
Solid tumours; Neoplasms; Papillomavirus Infections |
Details
|
HB-0028 |
HB-0028 |
Phase 2 Clinical |
Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Serositis; Ascites |
Details
|
CHECKvacc |
CF33-hNIS-antiPDL1 |
Phase 1 Clinical |
Imugene Ltd, City Of Hope National Medical Center |
Triple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
CYTO-102 |
CYTO-NK-102; CYTO-102; COH06 |
Phase 1 Clinical |
CytoImmune Therapeutics Inc |
Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
PM-8002 |
PM8002; PM-8002 |
Phase 2 Clinical |
Biotheus Inc |
Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Mesothelioma; Neuroendocrine Tumors; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
SGN-PDL1V |
SGN-PDL1V |
Phase 1 Clinical |
Seagen Inc |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Q-1802 |
Q-1802 |
Phase 1 Clinical |
Qiyu Biotechnology (Shanghai) Co Ltd |
Solid tumours; Gastrointestinal Neoplasms |
Details
|
Erfonrilimab |
KN-046; KN046 |
Phase 3 Clinical |
Suzhou Alphamab Co Ltd, Jiangsu Alphamab Biopharmaceuticals Co Ltd |
Colorectal Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Thymoma; Solid tumours; Thymus Neoplasms; Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms |
Details
|
Q-1801 |
Q-1801; Q 1801 |
Phase 1 Clinical |
Qiyu Biotechnology (Shanghai) Co Ltd |
Solid tumours |
Details
|
Acasunlimab |
PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 |
Phase 2 Clinical |
Genmab A/S, Biontech Se |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
IGM-7354 |
|
Phase 1 Clinical |
Igm Biosciences Inc |
Solid tumours |
Details
|
Recombinant anti-PD-L1/TGF-β bispecific antibody |
Y101D; Y-101D |
Phase 1 Clinical |
|
Solid tumours; Pancreatic Neoplasms; Carcinoma, Hepatocellular |
Details
|
6MW-3211 |
6MW3211; 6MW-3211 |
Phase 2 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Carcinoma, Renal Cell; Neoplasms; Myelodysplastic Syndromes; Lung Neoplasms; Lymphoma; Leukemia, Myeloid, Acute |
Details
|
Lodapolimab |
LY-3300054 |
Phase 1 Clinical |
Eli Lilly And Company |
Skin Melanoma; Solid tumours; Carcinoma, Renal Cell; Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Emfizatamab |
GNC-038 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell |
Details
|
LB-101 (Centessa Pharmaceuticals) |
LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody |
Phase 2 Clinical |
Centessa Pharmaceuticals Plc |
Solid tumours |
Details
|
ATG-101 |
ATG-101 |
Phase 1 Clinical |
Antengene Corporation Co Ltd |
Lymphoma, B-Cell; Solid tumours; Hematologic Neoplasms; Lymphoma, Non-Hodgkin; Neoplasm Metastasis |
Details
|
HB-0025 |
HB0025 |
Phase 2 Clinical |
Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Endometrial Neoplasms |
Details
|
BC008-1A |
BC008-1A |
Phase 1 Clinical |
Sichuan Luzhou Buchang Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
IMM-2520 |
IMM-2520 |
Phase 1 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours |
Details
|
HK-010 |
HK010; HK-010 |
Phase 1 Clinical |
Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd |
Neoplasms |
Details
|
Bintrafusp alfa |
M-7824; GSK-4045154; MSB-0011359C |
Phase 3 Clinical |
Merck Serono |
Gallbladder Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Sarcoma; Prostatic Neoplasms; Microsatellite Instability; Breast Neoplasms; Vulvar Neoplasms; Thymus Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Thymoma; Lung Neoplasms; Penile Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasm Metastasis; Sarcoma, Kaposi; Stomach Neoplasms; Biliary Tract Neoplasms; Intestinal Neoplasms; Head and Neck Neoplasms; Esthesioneuroblastoma, Olfactory; Carcinoma; Carcinoma, Renal Cell; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Vaginal Neoplasms; Anus Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Ganglioglioma; Nose Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Carcinoma, Transitional Cell; Respiratory papillomatosis; Adenomyoepithelioma |
Details
|
AUR-106 |
AUR-106 |
Phase 1 Clinical |
Aurigene Discovery Technologies Ltd |
Neoplasms |
Details
|
IMM2505 |
IMM2505; IMM-2505 |
Phase 1 Clinical |
Shenghe (China) Biopharmaceutical Co Ltd, ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours |
Details
|
GT-90008 |
GS-19-PLB-1C; GT-90008; GS-19 |
Phase 1 Clinical |
Suzhou Kintor Pharmaceuticals Inc |
Solid tumours |
Details
|
ND-021 |
ND-021; NM21-1480; CS-2006; CS2006 |
Phase 2 Clinical |
Numab Therapeutics Ag, Cstone Pharmaceuticals |
Solid tumours; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
MVR-C5252 |
C-5252; MVR-C5252 |
Phase 1 Clinical |
Immvira Co Ltd |
Solid tumours; Ganglioglioma; Glioblastoma; Brain Neoplasms |
Details
|
IMC-001 |
IMC-001; STI-3031; STI-A1015 |
Phase 2 Clinical |
Sorrento Therapeutics Inc |
Solid tumours; Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Neoplasm Metastasis |
Details
|
PM-8001 |
6MW3111; PM-8001 |
Phase 2 Clinical |
Biotheus Inc |
Solid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Retlirafusp alfa |
SHR-1701 |
Phase 3 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Pancreatic Neoplasms; Neoplasms; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
SIM-0237 |
SIM-0237 |
Phase 1 Clinical |
Simcere Pharmaceutical Group Ltd |
Solid tumours |
Details
|
PD-L1 peptide vaccine (IO Biotech) |
IO-103 |
Phase 2 Clinical |
Herlev Hospital, Io Biotech Aps |
Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Basal Cell; Smoldering Multiple Myeloma; Carcinoma, Non-Small-Cell Lung |
Details
|
Reozalimab |
IBI-318; LY-3434172; LY3434172 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company |
Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|